#Japan #Tokyo #GENOVA #ACVS #CLINIC BOT

GENOVA's Innovative Approach to Acute Cerebrovascular Syndrome Management

GENOVA, headquartered in Shibuya, Tokyo, is making strides in the healthcare sector by supporting a multi-professional collaboration initiative centered around the Acute Cerebrovascular Syndrome (ACVS). This initiative is driven by the Kanagawa Neurological Association, which has designed a response tool known as the `Blue Tool (Ver. 4.0)`. A key component of this effort is the adoption of GENOVA's LINE service, `CLINIC BOT`, as a technical means to facilitate the electronic utilization of the ACVS response tool.

The primary objective of this initiative is to enhance the quality of initial responses for cases suspected of suffering from stroke or transient ischemic attack (TIA) while preventing delays in medical consultations and referrals to specialists. Supported by the scientific and technological innovation co-creation initiative for the 7th year of Reiwa, this program underscores the significance of timely medical intervention in improving patient outcomes.

Background of the Collaboration

Stroke and TIA significantly depend on the time from onset to treatment initiation, affecting prognosis considerably. In instances where patients arrive able to walk, their symptoms might appear transient and mild, often leading to delayed decisions about seeking treatment and referrals to specialists. Challenges have also been identified regarding insufficient information sharing between healthcare, nursing, and local communities.

To address these concerns, the Kanagawa Neurological Association has developed the `Blue Tool`, which organizes critical information such as the time of onset, symptom recurrence, and the presence of atrial fibrillation, promoting a unified assessment framework among different professions in the healthcare field.

Overview of CLINIC BOT and the Blue Tool

In this collaborative project, GENOVA provides the `CLINIC BOT` LINE service as a supplementary means to enhance the usability of the `Blue Tool`. The implementation details include:

• - Digital conversion of symptom verification flows reflecting the principles of the `Blue Tool`
• - Systematic organization of symptoms based on BE-FAST criteria
• - Consolidation of high-risk indicators such as the time of onset and recurrence of symptoms
• - Guidance for rapid consultations and specialist referrals when high-risk conditions are suspected

It is essential to note that the LINE service is positioned primarily as a supportive technical tool for the operationalization of the `Blue Tool`.

Value to Medical Institutions and Patients

This initiative aims to deliver substantial value for both patients and medical institutions. For patients, it enhances the understanding of the significance of their symptoms, reducing uncertainty when deciding to seek medical help. For healthcare providers, it aims to prevent overlooking ACVS cases and improve the quality of initial responses. Moreover, the project fosters smooth collaboration with stroke centers and specialist physicians, enhancing regional healthcare networks.

Future Prospects

GENOVA plans to continue developing digital solutions by leveraging insights from professional associations and academic communities. The `CLINIC BOT` is envisioned as more than just a chatbot system; it is a platform aimed at enhancing healthcare quality and promoting positive behavioral changes in patients, contributing to the realization of a safer and more reliable healthcare experience.

Announcement of Multi-Professional Collaborative Healthcare Forum

Aiming for Zero Preventable Disabilities

ACVS indicates a precursor to strokes, and effective initial responses and swift collaboration can prevent severe strokes. This forum will discuss practical initiatives for seamless cooperation among physicians, nurses, caregivers, emergency services, and community healthcare providers to ensure ACVS is not overlooked.

Event Details

• - Date: February 7, 2026 (Saturday) 18:00–20:00 (Registration starts at 17:30)
• - Format: Hybrid (In-person + Web-based)
• - Location: TKP Yokohama Station West Exit Conference Center, Conference Room 1 (B2F)
• - Address: 2-24-1 Tsuruyamachi, Kanagawa Ward, Yokohama, Kanagawa Prefecture
• - Participation Fee: Free
• - Capacity: On-site: 50 people, Web: 500 people
• - Application Deadline: February 6, 2026 (Friday)
• - For more details, please refer to the provided PDF link.

About Kanagawa Neurological Association

The Kanagawa Neurological Association is composed of neurologists and neurosurgeons in Kanagawa Prefecture, aiming to enhance the quality of neurological disease diagnosis and promote regional healthcare collaboration.

Comments from Project Leader Dr. Yasuhiro Hasegawa

"Stroke is the leading cause of bedridden patients. To minimize sequelae, swift and appropriate initial treatment is essential. In cases where strokes manifest with transient or mild symptoms, all healthcare and caregiving professionals need to be adept at these procedures. The innovation brought by having accessible ACVS response criteria through familiar platforms like LINE can significantly improve initial care for suspected ACVS cases and contribute to extending healthy life expectancy."

About GENOVA

GENOVA is dedicated to creating a healthy society by connecting people with healthcare, tackling challenges such as the shortage of healthcare personnel due to Japan's aging population, and promoting improved healthcare access amidst increasing national medical costs. Our aim is to resolve the concerns and frustrations of patients and users regarding medical care and health, ultimately providing a higher quality healthcare experience.